VIVIMED LABS LTD.

Vivimed Labs Limited has issued a Form G inviting expressions of interest for its corporate insolvency resolution process. The company operates in the business of manufacturing pharma dosage forms across multiple locations in India, including Hyderabad, Haridwar, Kashipur, and Bidar. The filing provides details on installed capacities, revenue from operations for FY24-25 and FY23-24, and the number of employees. The last date for receipt of expressions of interest is June 29, 2026, with subsequent dates set for the provisional and final lists of prospective resolution applicants, and the submission of resolution plans.

The board meeting of Vivimed Labs Limited, previously scheduled for May 30, 2026, to approve the financial results for the quarter and year ended FY 2025-2026, has been postponed. The revised date will be communicated to the stock exchanges in due course. The trading window remains closed for designated persons until 48 hours after the financial results are declared following the rescheduled meeting.

Vivimed Labs Ltd has rescheduled its board meeting from May 28, 2026, to May 30, 2026, in Hyderabad. The meeting will consider and approve the audited financial results (standalone & consolidated) for the quarter and year ending March 31, 2026. The trading window remains closed for designated persons until 48 hours after the results are declared.

Vivimed Labs Ltd has scheduled a meeting of its Board of Directors on May 28, 2026, to consider and approve the audited financial results (standalone & consolidated) for the quarter and year ending March 31, 2026.

Vivimed Labs Ltd has been admitted to the Corporate Insolvency Resolution Process (CIRP) by the Hon’ble National Company Law Tribunal (NCLT), Bengaluru Bench, through an order dated April 15, 2026. The petition was filed by M/s Blue Cube Germany Assets GMBH & Co.KG, an operational creditor, under Section 9 of the Insolvency and Bankruptcy Code, 2016. The operational debt amounts to ₹32,78,60,844/-, inclusive of interest, arising from the company's failure to repay dues for perchloroethylene supplied between December 2012 and January 2014 by Dow Europe GmbH, whose rights were later acquired by Blue Cube Germany Assets. An Interim Resolution Professional (IRP) has been appointed, and the case is listed for June 24, 2026, awaiting the IRP report.

Vivimed Labs Ltd has announced the closure of its trading window in accordance with the Code of Conduct for Prohibition of Insider Trading and SEBI regulations. The trading window will remain closed from April 1, 2026 till 48 hours after the declaration of the financial results for the quarter and year ended March 31, 2026. The date of the Board-Meeting for the declaration of the financial results will be intimated in due course.

Vivimed Labs Ltd, a company listed on the National Stock Exchange of India, has announced its Q3 FY 2026 results. The company's standalone financial results show a profit before tax of Rs. 314.95 million for the quarter. The total revenue from operations stands at Rs. 1,392.85 million. The company's consolidated financial results also show a profit before tax of Rs. X (amount not provided) for the quarter. The financial results have been prepared in accordance with the Indian Accounting Standards and other accounting principles generally accepted in India.

Vivimed Labs Ltd, a company with CIN: LO2411KA1988PLCO09445, has announced that its Board of Directors will meet on 13th March 2026 to consider and approve the un-audited Financial Results (Standalone & Consolidated) for the quarter and nine months ending 31st December 2025. The meeting will take place at the company's registered office in Hyderabad, India.

Vivimed Labs Ltd, a company with CIN: LO2411KA1988PLC009465, has received a notice from the Central Bureau of Investigation, Banking securities Fraud Branch, Bengaluru. The notice was received under sections 94 & 179 BNSS, 120-B r/w 420, 468, 471, 477A IPC & 13(2) r/w 13 (1) (d) of Prevention of Corruption Act, 1988. The company had approached the High Court for the state of Telangana at Hyderabad, which granted an interim stay of all further proceedings pursuant to the impugned search & seizure. This includes restraining from taking any coercive steps against Vivimed Labs Limited, Its Directors etc on the basis of search & seizure conducted on 20.01.2026 and on the basis of complaint/and or notification of declaration by State Bank of India of the Vivimed Labs Limited Account as ‘fraud’ in any manner whatsoever, until further orders by the Hon’ble High Court for the state of Telangana at Hyderabad.

Vivimed Labs Ltd. has filed an application for the initiation of a Pre-pack Insolvency Resolution Process (PPIRP) with the Insolvency and Bankruptcy Board of India (NCLT Bengaluru Bench) as of 12th February 2026. The default amount stands at INR 512,53,06,756 (Five hundred twelve crores fifty three lakhs six thousand seven hundred and fifty six rupees) as of 31st January 2026, as per the regulations outlined in SEBI(LODR) 2015, Regulation 30.